First Patient Enrolled in Phase 3 Trial of Abelacimab for High-Risk Atrial Fibrillation Patients
Anthos Therapeutics has enrolled the first patient in a Phase 3 study to evaluate the efficacy and safety of abelacimab in high-risk patients with atrial fibrillation deemed unsuitable for current ant ...
Evaxion has received FDA approval to move forward with a Phase 2b clinical study for EVX-01
Evaxion Biotech A/S, a clinical-stage biotech company, announced that the FDA had given the green light for their Phase 2b clinical trial of EVX-01. The Company submitted an IND and Fast Track applica ...